Abstract
Executive Summary
The commercial and therapeutic success of antibodies like Rituxan, Avastin,
and Erbitux will force the industry to look into the next generation of
therapeutic antibodies, preparing themselves for the second wave in the
lucrative field of therapeutic antibodies. Today, there are more than 330
companies plus partners developing more than 450 antibody based oncology drugs
in more than 880 developmental projects. In addition, the accumulated number
of ceased drugs over the last three years amount to another 192 drugs. In all,
these antibody based drugs target around 71 different cancer indications. The
number of antibody targets has increased to over 240 described molecular
targets in just a few years. These targets are further categorized on the
CD-ROM by 56 classifications of molecular function and with pathway referals
to BioCarta, KEGG and NetPath. Read more below on how the Antibody in
Oncology: Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
- Show investors/board/management that you are right on top of drug
development progress in your therapeutic area.
- Find competitors, collaborations partners, M&A candidates etc.
- Jump start competitive drug intelligence operations
- Excellent starting point for world wide benchmarking
- Compare portfolio and therapy focus with your peers
- Speed up pro-active in-/out licensing strategy work
- Fast and easy way of tracking drugs using search engines; just one click
from inside the application and you may search the World Wide Web and PubMed
for any drug.
- Drug Pipeline Update is delivered to you as a CD-ROM application, which
requires no installation on your computer. Please read more about application
features and system requirements below.
| 
View Cart
